LONDON, March 25 (Reuters) - Vectura Group PLC:
* Positive phase II data for vr496
* VR496 demonstrates anti-inflammatory and mucolytic activity in cystic fibrosis patients
* This study confirms the potential therapeutic benefit of VR496 in a variety of airway disorders and justifies further clinical evaluation
* These data will be of value in our on-going discussions with prospective licensing partners
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Positive phase II data for vr496
* VR496 demonstrates anti-inflammatory and mucolytic activity in cystic fibrosis patients
* This study confirms the potential therapeutic benefit of VR496 in a variety of airway disorders and justifies further clinical evaluation
* These data will be of value in our on-going discussions with prospective licensing partners
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.